Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC

Official record

Identifier

NCT07847671

Recruiting locations

country

China

Interventions studied

FMT combined with QL1706 plus Bevacizumab

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital

Target enrolment

20 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Not yet recruiting

First posted

Sep 29, 2026

Last updated on the registry

Sep 29, 2026

Age

18 Years – 75 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Age \>18 years.
* Confirmed imaging or histological diagnosis of unresectable HCC.
* Treatment-naïve unresectable or metastatic HCC.
* BCLC Stage C.
* Child-Pugh A.
* ECOG PS 0-1.

Main Exclusion Criteria:

* Prior treatment with an immune checkpoint inhibitor, or prior systemic therapy for advanced HCC.
* Histologic subtypes other than hepatocellular carcinoma, including fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular cholangiocarcinoma.
* Active or prior autoimmune disease, immunodeficiency requiring systemic immunosuppressive therapy.
* Clinically significant bleeding risk, coagulopathy, or untreated high-risk esophagogastric varices.
* Any contraindication to fecal microbiota transplantation.
* Uncontrolled intercurrent illness, including active infection, clinically significant cardiovascular disease, central nervous system metastases.
* Pregnancy or breastfeeding.

Indexed under

Liver Cancer